The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13)

Annals of Hematology

Volumn 90, Issue 6, 2011, Pages 709-717

  Dong, Hua Jie ^a   Zhou, Li Tao ^a   Zhu, Dan Xia ^a   Wang, Dong Mei ^a   Fang, Cheng ^a   Zhu, Hua Yuan ^a   Zhuang, Yun ^a   Miao, Kou Rong ^a   Xu, Wei ^a   Li, Jian Yong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chronic lymphocytic leukemia; Deletion; Mutation; p53 gene

Indexed keywords

ANTINEOPLASTIC AGENT; FLUDARABINE;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CHINESE; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; COHORT STUDIES; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79956071061     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-010-1125-8     Document Type: Article

References (21)

1. Xu W, Li JY, Wu YJ et al (2008) Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia. Leuk Res 32:1071-1077 (Pubitemid 351514787)
2. Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352:804-815
3. Berkova A, Pavlistova L, Babicka L et al (2008) Combined molecular biological and molecular cytogenetic analysis of genomic changes in 146 patients with B-cell chronic lymphocytic leukemia. Neoplasma 55:400-408
4. Lin K, Sherrington PD, Dennis M et al (2002) Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 100:1404-1409
5. Pettitt AR, Sherrington PD, Stewart G et al (2001) p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 98:814-822
6. Rossi D, Cerri M, Deambrogi C et al (2009) The prognosis value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13. Clin Cancer Res 15:995-1004
7. Lozanski G, Heerema NA, Flinn IW et al (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278-3281 (Pubitemid 38525651)
8. Krober A, Bloehdorn J, Hafner S et al (2006) Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 24:969-975 (Pubitemid 46646223)
9. Hallek M, Cheson BD, Catovsky D et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines. Blood 111:5446-5456
10. Dicker F, Herholz H, Schnittger S et al (2009) The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 23:117-124
11. Zenz T, Habe S, Denzel T et al (2009) Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114:2589-2597
12. Zenz T, Eichhorst B, Busch R et al (2010) TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28:4473-4479
13. Mayr C, Speicher MR, Kofler DM et al (2006) Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 107:742-751 (Pubitemid 43076401)
14. Thornton PD, Gruszka-Westwood AM, Hamoudi RA et al (2004) Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol J 5:47-54 (Pubitemid 38262790)
15. Grever MR, Lucas DM, Dewald GW et al (2007) Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25:799-804 (Pubitemid 350010635)
16. Zenz T, Krober A, Scherer K et al (2008) Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 112:3322-3329
17. Grever MR, Lucas DM, Johnson AJ, Byrd JC (2007) Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol 20:545-556 (Pubitemid 47250499)
18. Best OG, Gardiner AC, Majid A et al (2008) A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia 22:1456-1459 (Pubitemid 352006096)
19. Sturm I, Bosanquet AG, Hermann S et al (2003) Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 10:477-484 (Pubitemid 36626360)
20. Petitjean A, Mathe E, Kato S et al (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629 (Pubitemid 46744292)
21. Soussi T, Asselain B, Hamroun D et al (2006) Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin Cancer Res 12:62-69 (Pubitemid 43166177)